Latest news with #EXPRESSION
Business Upturn
13 hours ago
- Business
- Business Upturn
SVP Worldwide Announces Global Launch of Three New PFAFF® Sewing Machines: creative expression™ 750, quilt expression™ 725, and expression™ 715
Business Wire India SVP Worldwide, the parent company of PFAFF®, SINGER®, and HUSQVARNA® VIKING® sewing brands, today announced the highly anticipated global launch of three new PFAFF sewing machines: the creative expression 750, quilt expression 725, and expression 715. These machines combine precision engineering, cutting-edge technology, and the timeless craftsmanship PFAFF is known for. This press release features multimedia. View the full release here: SVP Worldwide, the parent company of PFAFF (R), launches three new sewing machines: the creative expression 750, quilt expression 725 and expression 715. The machines combine precision engineering, cutting-edge technology, and the timeless craftsmanship PFAFF is known for globally. The new models will be available for purchase beginning August 14, 2025 on and at authorized PFAFF Dealer locations across the United States and Europe. Expanded global distribution in Latin America and Asia Pacific is planned throughout Q3 and Q4 of 2025. "This launch represents an exciting new chapter for PFAFF and for passionate sewists around the world," said Rob Will, CEO of SVP Worldwide. "These three machines are designed to inspire creativity and confidence, offering the precision and innovation that our customers expect from the PFAFF brand. We can't wait to see the extraordinary projects our 'PFAFFies' will bring to life with this new lineup." The new expression series machines showcase advanced features tailored to both serious hobbyists and professional sewists. All models offer: Built-in connectivity to the CREATIVATE™ digital platform of creative tools Large color capacitive touch screens for an intuitive, modern sewing experience for an intuitive, modern sewing experience Automatic Needle Threaders eliminate threading frustration Exclusive PFAFF stitch techniques for distinctive embellishments The creative expression 750 and quilt expression 725 also feature adjustable laser sewing guidance, enabling users to achieve unmatched accuracy for complex projects. "The new PFAFF expression series brings together precision and innovation in a way that truly elevates the sewing experience," said Jason Zielke, Chief Product and Technology Officer at SVP Worldwide. "We are especially proud of the new Hoop Scanning feature on the creative expression 750, which allows a sewist to see their hooped project on the 8' color touch screen for a more accurate placement of the embroidery before stitching." The launch of the PFAFF creative expression 750, quilt expression 725, and expression 715 reaffirms SVP Worldwide's commitment to empowering creators worldwide with products that push the boundaries of sewing technology and innovation. For more information or to locate a dealer, visit PFAFF, SINGER, VIKING, CREATIVE EXPRESSION, QUILT EXPRESSION, EXPRESSION and CREATIVATE are exclusive trademarks of Singer Sourcing Limited LLC or its Affiliates. HUSQVARNA and the 'H' Crown Device are trademarks of Husqvarna AB and are used under license. © 2025 Singer Sourcing Limited LLC or its Affiliates. All rights reserved. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
2 days ago
- Business
- Business Wire
SVP Worldwide全球首发三款全新PFAFF®缝纫机：creative expression™ 750、quilt expression™ 725及expression™ 715
纳什维尔，田纳西州--(BUSINESS WIRE)--(美国商业资讯)-- 缝纫品牌PFAFF®、SINGER®和HUSQVARNA® VIKING®的母公司SVP Worldwide今天宣布在全球推出三款备受期待的全新PFAFF缝纫机： creative expression 750 、 quilt expression 725 和 expression 715 。这些机型融合精密工程、前沿科技与PFAFF品牌传承的匠心工艺。 新款机型将于起通过 及 PFAFF欧美授权经销商 发售，并计划于2025年第三、四季度 拓展至拉丁美洲和亚太地区市场 。 '此次发布标志着PFAFF品牌与全球缝艺爱好者共同开启激动人心的新篇章。 ' SVP Worldwide首席执行官Rob Will 表示， '这三款机型旨在激发创造力与信心，以用户期待的精准和创新延续PFAFF品牌传奇。我们已迫不及待想看到广大PFAFF爱好者用此全新系列机型创作的惊艳作品。' 全新 expression系列 搭载多项 先进功能 ，满足资深手工爱好者与专业匠人的需求。全部机型均具备以下特性： 内置接入CREATIVATE™数字创意工具平台 大尺寸彩色电容触控屏 带来直观现代的缝纫体验 自动穿线器解决穿线难题 独家PFAFF针法技术 实现独特装饰效果 其中 creative expression 750 和 quilt expression 725 还配备 可调激光缝纫引导系统 ，让用户在复杂项目实现无与伦比的精确度。 '全新PFAFF expression系列将精确性和创新性融为一体，真正提升了缝纫体验。 ' SVP Worldwide首席产品与技术官Jason Zielke 指出， '我们特别为creative expression 750的全新绣框扫描功能自豪，8英寸彩色触控屏可显示绣框内项目，实现刺绣前的精准定位。' 此次发布 PFAFF creative expression 750、quilt expression 725和expression 715 再次彰显SVP Worldwide致力于通过突破缝纫科技边界的产品赋能全球创作者的承诺。 要了解更多信息或查找经销商，请访问 。 PFAFF、SINGER、VIKING、CREATIVE EXPRESSION、QUILT EXPRESSION、EXPRESSION及CREATIVATE均为Singer Sourcing Limited LLC或其关联公司独家商标。HUSQVARNA及"H"皇冠标志系Husqvarna AB商标，经许可使用。©2025 Singer Sourcing Limited LLC或其关联公司。保留所有权利。 免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
Business Wire
2 days ago
- Business
- Business Wire
SVP Worldwide Announces Global Launch of Three New PFAFF® Sewing Machines: creative expression™ 750, quilt expression™ 725, and expression™ 715
NASHVILLE, Tenn.--(BUSINESS WIRE)--SVP Worldwide, the parent company of PFAFF®, SINGER®, and HUSQVARNA® VIKING® sewing brands, today announced the highly anticipated global launch of three new PFAFF sewing machines: the creative expression 750, quilt expression 725, and expression 715. These machines combine precision engineering, cutting-edge technology, and the timeless craftsmanship PFAFF is known for. The new models will be available for purchase beginning August 14, 2025 on and at authorized PFAFF Dealer locations across the United States and Europe. Expanded global distribution in Latin America and Asia Pacific is planned throughout Q3 and Q4 of 2025. "This launch represents an exciting new chapter for PFAFF and for passionate sewists around the world," said Rob Will, CEO of SVP Worldwide. "These three machines are designed to inspire creativity and confidence, offering the precision and innovation that our customers expect from the PFAFF brand. We can't wait to see the extraordinary projects our 'PFAFFies' will bring to life with this new lineup." The new expression series machines showcase advanced features tailored to both serious hobbyists and professional sewists. All models offer: Built-in connectivity to the CREATIVATE™ digital platform of creative tools Large color capacitive touch screens for an intuitive, modern sewing experience Automatic Needle Threaders eliminate threading frustration Exclusive PFAFF stitch techniques for distinctive embellishments The creative expression 750 and quilt expression 725 also feature adjustable laser sewing guidance, enabling users to achieve unmatched accuracy for complex projects. "The new PFAFF expression series brings together precision and innovation in a way that truly elevates the sewing experience," said Jason Zielke, Chief Product and Technology Officer at SVP Worldwide. "We are especially proud of the new Hoop Scanning feature on the creative expression 750, which allows a sewist to see their hooped project on the 8' color touch screen for a more accurate placement of the embroidery before stitching." The launch of the PFAFF creative expression 750, quilt expression 725, and expression 715 reaffirms SVP Worldwide's commitment to empowering creators worldwide with products that push the boundaries of sewing technology and innovation. For more information or to locate a dealer, visit PFAFF, SINGER, VIKING, CREATIVE EXPRESSION, QUILT EXPRESSION, EXPRESSION and CREATIVATE are exclusive trademarks of Singer Sourcing Limited LLC or its Affiliates. HUSQVARNA and the 'H' Crown Device are trademarks of Husqvarna AB and are used under license. © 2025 Singer Sourcing Limited LLC or its Affiliates. All rights reserved.
Yahoo
20-03-2025
- Business
- Yahoo
AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community
Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess® (RelabotulinumtoxinA) highlighting its rapid onset of action as early as day one and sustained high patient satisfaction beyond six months1,2 New in vivo data on Sculptra® (PLLA-SCA), the first proven regenerative biostimulator, will be presented, showing its lower inflammatory response compared to PLLA-GA, which can significantly impact local tissue response and product degradation and therefore may impact the duration of clinical effect3-12 Additionally, results from the first-of-its-kind and largest survey on facial changes associated with medication-driven weight loss will be presented showing many patients would consider aesthetic treatments to address these changes, with biostimulators and dermal fillers the most frequently considered13 Galderma will host a symposium exploring how aesthetic treatments can address facial changes associated with medication-driven weight loss in addition to a second symposium dedicated to achieving the ideal lips with Restylane® Kysse™ In total, Galderma will present 11 e-posters, including additional updates on Restylane, and host two symposia, four Masterclass sessions, five Meet-the-Expert sessions, an experiential lounge and an interactive booth, reinforcing its strong leadership position in Injectable Aesthetics ZUG, Switzerland, March 20, 2025--(BUSINESS WIRE)--Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions. This extensive program highlights the breadth of Galderma's leading Injectable Aesthetics portfolio, designed to address the present and future needs of patients and healthcare professionals alike. "With our extensive presence at AMWC 2025, we have a valuable platform to engage with the aesthetics community while showcasing the broadest portfolio in the industry. Through our data presentations and expert-led sessions, we reaffirm our commitment to being a leading force in advancing the field of Injectable Aesthetics and equipping healthcare professionals with the innovative solutions they need to fulfill the needs of patients, today and tomorrow." BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA Expert perspectives on the hottest topics in injectable aesthetics today Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with alterations in facial aesthetic appearance of variable magnitude.14 In the largest study investigating facial changes in medication-driven weight loss to date, Galderma surveyed more than 1,300 people across five countries.13 Findings from this first-of-its kind study will be presented, showing 93% of those undergoing weight loss treatment noticed some degree of facial changes during their treatment and many patients are considering aesthetic treatments to address these, with biostimulators and dermal fillers being the most frequently considered treatments.13 The Galderma-sponsored "Medication-Driven Weight Loss: The Algorithms" symposium taking place on Thursday, March 27, as well as a dedicated Masterclass session on Friday, March 28, will explore the effects medication-driven weight loss can have on the face and dive into the ways aesthetic procedures can help restore facial volume and structure. The symposium will feature live demonstrations and expert insights from Dr. Luiz Avelar, Dr. Priyanka Chadha, Prof. Sebastian Cotofana, Dr. Sabrina Fabi, Dr. Marcus Morais, and Dr. Andreas Nikolis. Galderma will also host the "GAIN Experts Dialogue: Defining the Ideal Lips" symposium on Thursday, March 27, featuring expert speakers Prof. Sebastian Cotofana, Dr. Simone Doreian, Dr. Stephanie Lam, Dr. Christoph Martschin, and Dr. Andrei Metelitsa. This session, through insightful debates, cultural and anatomical discussions, and live injection demonstrations, will explore the evolving techniques in aesthetic lip treatments as well as patient standards and preferences for natural looking and feeling results. A Masterclass session will also be held to dive deeper into these techniques on Saturday, March 29. New data cements the unique ability of Galderma's products to meet patient needs Galderma will present new data from the phase IIIb EXPRESSION and RELAX studies, showing Relfydess achieved rapid onset of action and significant aesthetic improvement in frown lines and crow's feet.1,2 In the EXPRESSION study more than 50% of patients reported visible effects as early as day one and, in the RELAX study, effects were sustained through six months, confirming results seen in the READY trial program and more than a third saw improvement beyond six months in frown lines.1,2 Both studies re-confirmed high patient satisfaction with Relfydess, with 70% of patients in the RELAX study reporting that they preferred treatment with Relfydess versus prior treatments received.1,2 Encore data from a post-hoc analysis of the phase III READY program will show that, regardless of baseline wrinkle severity (moderate/severe), subjects treated with Relfydess achieved high rates of improvement in frown lines and crow's feet, along with improved well-being, and a sustained effect through six months.15 Galderma will also present new data on Sculptra (PLLA-SCA), the first proven regenerative biostimulator, reinforcing its unique formulation, efficacy, and safety.3-12 New in vivo comparative data will demonstrate its favorable tissue response and slower, controlled product degradation profile at 52 weeks, as well as lower inflammation, compared to PLLA-GA.11 The lower inflammation is consistent with Sculptra's well-established safety profile.3 Differences in formulation can significantly impact local tissue response and product degradation, affecting potential clinical outcomes such as efficacy and duration.11 An expert consensus also confirms Sculptra's key role in the regenerative aesthetic field and additional data will show its synergistic effect when paired with Alastin®, underscoring its effect across all three skin layers.12,16 Encore data to be presented on Restylane Shaype™, powered by Galderma's proprietary NASHA HD™ Technology and approved in Canada and most recently in Brazil, will show that it constitutes a breakthrough innovation in hyaluronic acid fillers as the firmest hyaluronic acid injectable available and displaying the highest G-prime (indicating superior gel strength and firmness) on the market providing a unique bone mimicking effect.17,18 Additional pooled and pivotal phase IV data to be presented will show that Restylane fillers preserve or enhance the natural expressions of 98% of patients while achieving desired aesthetic improvements in attractiveness and youthfulness.19 This naturalness, combined with high patient satisfaction, represents long-lasting aesthetic improvement.19 To date, Restylane is the first and only hyaluronic acid filler to have in vivo data demonstrating its efficacy in restoring and maintaining the naturalness of expression.19-22 These e-posters, along with others presented on Dysport® and Alastin, will reinforce Galderma's strong dedication to equipping practitioners with the products they need to achieve natural, long-lasting results for their patients. More details on Galderma's scientific presentations at AMWC can be found here. Media can watch this video to find out more about facial changes associated with medication-driven weight loss and this video to learn more about the natural looking results of Restylane products. About Relfydess (RelabotulinumtoxinA) Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity.23 PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.24-27 Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.23,28 It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Relfydess received a marketing authorization in several markets. RelabotulinumtoxinA is an investigational drug product in the U.S. Authorization conditions may vary internationally. About the Restylane Portfolio Restylane hyaluronic acid (HA) injectables are Designed Differently to go beyond volumizing for natural-looking results.29-32 Our HA is exceptionally pure, making it the closest to the skin's own.33 Our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose. Restylane unique technologies, NASHA HD™, NASHA® and OBT™ are meaningfully designed to mimic the diverse range of facial structures and skin layers.29-31 With the Highest G' and Highest flexibility, Restylane can provide from structural support to natural expression to a healthy glow.17,30,33-36 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural looking results.22,29,37 About Sculptra Sculptra is the first proven regenerative biostimulator, with a unique PLLA-SCA™ formulation that helps restore the deep, underlying structure of the skin by inducing a foreign body reaction.3,48-10,38-47 Sculptra works to address the underlying causes of facial aging, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.3,41,45-47 Sculptra encourages the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore facial volume and the look of fullness to wrinkles and folds over time.48-51 The results from Sculptra are long-lasting, with optimal correction seen in approximately three months and results lasting up to two years.4,46,7,52 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References Shridharani S, Coquis-knezek S and Prygova I. Aesthetic improvement and rapid results in glabellar and lateral canthal lines after treatment with the innovative liquid relabotulinumtoxinA formulation. Presented at AMWC 2025; Mar 27-29, 2025; Monaco Ablon G, et al. Subject preference and satisfaction with liquid relabotulinumtoxinA treatment of glabellar lines over 12 months, in a randomized controlled trial. Presented at AMWC 2025; Mar 27-29, 2025; Monaco Galderma. Sculptra EU Instructions For Use 2023 Widgegrowl J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds). IMCAS Poster 2024. Paris, France Galderma. Data on file. MA-50526. 43USSA1812 clinical study report. Fort Worth, TX: Galderma Laboratories, L.P. 2022 Bohnert K, et al. Randomized, Controlled, Multicentered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid for Improving Skin Quality. Dermatol Surg 2019;45:718–724 Hexsel D, et al. Introducing the L-Lift—A Novel Approach to Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg: Letters & Communications. 2019 Galderma. Data on File (MA-60875) Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042 Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791 Avelar L, et al. Comparing two biostimulators on the local tissue response and degradation up to 52 weeks in vivo with an indirect comparison to clinical outcomes. Presented at AMWC 2025; Mar 27-29, 2025; Monaco Fabi S, et al. Regenerative aesthetic effects of poly L-lactic acid (PLLA-SCA) treatment. Presented at AMWC 2025; Mar 27-29, 2025; Monaco Nikolis A, Prygova I and Brasatar D. The potential role of biostimulators/dermal fillers to address the impact of medication driven weight loss management treatments on facial appearance. Presented at AMWC 2025; Mar 27-29, 2025; Monaco Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721 Ablon G, et al. RelaBoNT-A treatment of glabellar lines and lateral canthal lines of different baseline severity: subgroup analyses of pooled Phase III study data. Presented at AMWC 2025; Mar 27-29, 2025; Monaco Markowitz O, et al. Evaluation of synergistic effects for midface improvement when pairing Sculptra® (PLLA-SCA) with Alastin skincare®: A comparative study. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco Bromée T, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–61. doi: 10.36849/JDD.8145 Nkolis A, et al. Hyaluronic acid fillers preserve natural movement and dynamic expression: data from three postmarketing clinical studies. Presented at AMWC 2025; Mar 27-29, 2025; Monaco Percec, I et al. An Objective, Quantitative, Dynamic Assessment of Hyaluronic Acid Fillers That Adapt to Facial Movement. Plast Reconstr Surg. 2020;145:295e–305e. doi: 10.1097/PRS.0000000000006461 Philipp-Dormston WG, et al. Evaluating Perceived Naturalness of Facial Expression After Fillers to the Nasolabial Folds and Lower Face With Standardized Video and Photography. Dermatol Surg. 2018;44(6):826–32. doi: 10.1097/DSS.0000000000001419 Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738–46. doi: 10.1111/jocd.12961 Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. ASJ. 2024; sjae131 Ablon G, et al. Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study. Dermatol Surg. 2024. doi: 10.1097/DSS.0000000000004470 Relfydess®. EU Summary of Product Characteristics Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin Di Gregorio C. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC, March 27-29, 2024, Monaco Nikolis A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12. Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021 Restylane U.S. Instructions For Use. Available online. Accessed January 2025. Kablik J, et al. Comparative Physical Properties of Hyaluronic Acid Dermal Fillers: Dermatologic Surgery 35, 302–312 (2009). Narins RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644–650 Talarico S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361–1369 Ohrlund A, et al.. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. JDD. 2024; 23(1), pp.1332-1336 Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-6. U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed January 2025. Galderma. Data on File (MA-46589) Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi:10.1186/1471233414474 Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755 Asius J, et al. Inventors. US patent US 7,731,758 B2.2010. Available online. Accessed January 2025 Morgan P, et al. Product Manufacturing Process for Poly-L-lactic acid (PLLA-SCA). Poster presented at IMCAS World Congress, January 26–28, 2023, Paris, France Galderma. Data on File (MA-53568) Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43. doi: 10.1111/ Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–22 Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48: 101–108. doi: 10.1097/DSS.0000000000003239 Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229 Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51 Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC, March 30 - April 1, 2023, Monaco View source version on Contacts For further information: Christian Marcoux, Communications +41 76 315 26 50 Sébastien CrosCorporate Communications +41 79 529 59 85 Emil IvanovHead of Strategy, Investor Relations, and +41 21 642 78 12 Jessica CohenInvestor Relations and Strategy +41 21 642 76 43 Sign in to access your portfolio
